Rebecca Beerman

Program Mgr, Clinical Data Mgmt

Duke University

rebecca.beerman@duke.edu

MSRB II Building, Rm 1089, 2 Genome Court, Box 102800, Durham, NC 27710

2 Genome Court, MSRB II Building. Rm 1089, Durham, NC 27710

More About This Person

At a Glance

Credentials

Academic Experience
1. Current Appointments & Affiliations

Expertise
1. Keywords

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Selected Grants

External Quality Assurance Program Oversight Laboratory (EQAPOL)

ResearchClinical Data Manager · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2031

CEPI QAU

ResearchProduct Manager · Awarded by Imperial College London · 2025 - 2029

BNT165-02

ResearchProject Manager · Awarded by BioNTech SE · 2025 - 2028

HVTN Laboratory Center: Phase 1 PF

ResearchQuality Assurance Analyst · Awarded by Fred Hutchinson Cancer Center · 2022 - 2027

HIV Vaccine Trials Network Laboratory Center

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2027

Sc2i Competitive Renewal

ResearchQA Liaison · Awarded by Henry M. Jackson Foundation · 2021 - 2027

Tuberculosis (M72) Immune Correlates

ResearchQuality Management Coordinator · Awarded by Bill and Melinda Gates Medical Research Institute · 2025 - 2026

CIVICs Component A Year 7 - Option 6

ResearchProgram Manager · Awarded by National Institutes of Health · 2019 - 2026

Antibody Dynamics for BNT165b1

ResearchClinical Data Manager · Awarded by BioNTech SE · 2023 - 2026

Immunogenicity (Serum IgG)

ResearchProgram Manager · Awarded by Uvax Bio, LLC · 2024 - 2026

CoVPN 3008 TB Study

ResearchQuality Management Coordinator · Awarded by Fred Hutchinson Cancer Center · 2025 - 2025

IMPAACT 2042

ResearchQuality Management Coordinator · Awarded by Johns Hopkins University · 2025 - 2025

CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024

A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years

ResearchProject Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment

ResearchProgram Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024

CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe

ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls

ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin

ResearchProgram Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023

CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

ResearchProgram Manager · Awarded by Seattle Cancer Care Alliance · 2022 - 2022

CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older

ResearchData Manager · Awarded by Seattle Cancer Care Alliance · 2022 - 2022

A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A

ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2022

HVTN Laboratory Center: Phase 1 PF

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022

CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022